ASX Biotech Stocks
Clinical-stage developers and commercial pharma, ranked by short interest.
15 constituents · short positions as of · ASIC data, T+4 delay
Median short
1.34%
across 15 constituents
Most shorted
TLX
10.39% of issued capital
Biggest 4-week riser
CSL
+0.35pp in 4 weeks
Above 5% short
4
of 15 constituents
Theme short interest over time
Weekly average · shaded band is the constituent rangeConstituents
| Code | Company | Industry | Short % | Δ 4w | Price | Δ 1m | Days to cover |
|---|---|---|---|---|---|---|---|
| TLX | Telix Pharmaceuticals | Pharmaceuticals, Biotechnology & Life Sciences | 10.39% | -1.2pp | $15.62 | +5.1% | 19.5 |
| CUV | Clinuvel Pharmaceuticals | Pharmaceuticals, Biotechnology & Life Sciences | 8.50% | -0.4pp | $10.89 | +8.4% | 41.6 |
| CU6 | Clarity Pharmaceuticals | Pharmaceuticals, Biotechnology & Life Sciences | 8.35% | +0.1pp | $2.62 | +17.5% | 13.3 |
| MSB | Mesoblast | Pharmaceuticals, Biotechnology & Life Sciences | 7.44% | -0.1pp | $2.51 | +8.2% | 38.6 |
| NEU | Neuren Pharmaceuticals | Pharmaceuticals, Biotechnology & Life Sciences | 4.46% | -0.6pp | $23.14 | +38.1% | 9.3 |
| IMM | Immutep | Pharmaceuticals, Biotechnology & Life Sciences | 2.37% | -1.3pp | $0.05 | — | 5.2 |
| MYX | Mayne Pharma Group | Pharmaceuticals, Biotechnology & Life Sciences | 2.28% | -0.1pp | $3.35 | +21.8% | 6.2 |
| CSL | Csl | Pharmaceuticals, Biotechnology & Life Sciences | 1.34% | +0.3pp | $171.20 | +41.0% | 4.3 |
| BOT | Botanix Pharmaceuticals | Pharmaceuticals, Biotechnology & Life Sciences | 0.58% | +0.1pp | $0.02 | — | 2.0 |
| IMU | Imugene | Pharmaceuticals, Biotechnology & Life Sciences | 0.39% | -0.8pp | $0.08 | -11.1% | 1.0 |
| PYC | Pyc Therapeutics | Pharmaceuticals, Biotechnology & Life Sciences | 0.17% | -0.1pp | — | — | — |
| AVH | Avita Medical Inc. | Pharmaceuticals, Biotechnology & Life Sciences | 0.15% | -0.1pp | $2.82 | +93.2% | 0.2 |
| PAR | Paradigm Biopharmaceuticals Limited.. | Pharmaceuticals, Biotechnology & Life Sciences | 0.08% | +0.1pp | — | — | — |
| DXB | Dimerix | Pharmaceuticals, Biotechnology & Life Sciences | 0.01% | -0.0pp | $0.32 | +39.1% | 0.0 |
| OPT | Opthea | Pharmaceuticals, Biotechnology & Life Sciences | 0.01% | -0.5pp | — | — | — |
Membership is curated and verified against company metadata — a wrong member is worse than a missing one. Refine further in the screener.
Latest biotech news
- Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? - thebull.com.au
TLX · googlenews
- Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays - simplywall.st
TLX · googlenews
- Telix shares are tumbling. Is the stock finally at fair value?
TLX · motleyfool
- CLINUVEL Annual Results - Investor Webinar
CUV · asx
- Becoming a substantial holder
CUV · asx
- CLINUVEL's injectable peptide platform
CUV · asx
- Becoming a substantial holder
CU6 · asx
- Clarity Pharmaceuticals Ltd (ASX:CU6) Stock Slides: What Investors Should Know - Kalkine
CU6 · googlenews
About this theme
Biotech short interest is priced off binary events. A clinical-stage company's value rests on trial readouts and regulatory decisions whose dates are public, so positions build ahead of them and clear immediately afterwards — the sharpest short-interest moves in this theme are calendar-driven rather than gradual. Between those dates the recurring bear case is dilution: companies without revenue fund trials by issuing stock, and a raise at a discount is the outcome a short is positioned for. Commercial-stage names attract a different argument about reimbursement decisions, competitor launches and the cost of building a sales force in the United States. The asymmetry is what makes this basket distinctive: an approval or a licensing deal can multiply a small-cap price overnight, so a crowded short in a thinly traded developer carries loss potential unlike anything in the mining or banking themes.
Short positions come from official ASIC short position reports (published with a T+4 trading-day delay) joined with daily price and volume data. The chart averages the constituents reporting in each week and shades the range between the least and most shorted of them; a member with no data that week is absent from the average rather than counted as zero.